Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 20406836)

1.

Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer.

Soliman H, Gunasekara A, Rycroft M, Zubovits J, Dent R, Spayne J, Yaffe MJ, Czarnota GJ.

Clin Cancer Res. 2010 May 1;16(9):2605-14. doi: 10.1158/1078-0432.CCR-09-1510. Epub 2010 Apr 20.

2.

Functional imaging of neoadjuvant chemotherapy response in women with locally advanced breast cancer using diffuse optical spectroscopy.

Soliman H, Yaffe MJ, Czarnota GJ.

Conf Proc IEEE Eng Med Biol Soc. 2009;2009:3244-6. doi: 10.1109/IEMBS.2009.5333532.

PMID:
19964289
3.

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.

Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.

J Surg Oncol. 2002 May;80(1):4-11.

PMID:
11967899
4.

Imaging breast cancer chemotherapy response with light. Commentary on Soliman et al., p. 2605.

Tromberg BJ, Cerussi AE.

Clin Cancer Res. 2010 May 1;16(9):2486-8. doi: 10.1158/1078-0432.CCR-10-0397. Epub 2010 Apr 20.

5.

Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study.

Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg BJ.

J Biomed Opt. 2005 Sep-Oct;10(5):051503.

PMID:
16292947
6.

Monitoring the response to primary medical therapy for breast cancer using three- dimensional time-resolved optical mammography.

Enfield LC, Cantanhede G, Westbroek D, Douek M, Purushotham AD, Hebden JC, Gibson AP.

Technol Cancer Res Treat. 2011 Dec;10(6):533-47.

PMID:
22066594
7.

Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy.

Cerussi A, Hsiang D, Shah N, Mehta R, Durkin A, Butler J, Tromberg BJ.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9. Epub 2007 Feb 28.

8.

Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.

Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, Stirling JJ, d'Arcy JA, Collins DJ, Pittam MR, Ravichandran D, Padhani AR.

Clin Cancer Res. 2008 Oct 15;14(20):6580-9. doi: 10.1158/1078-0432.CCR-07-4310.

9.
10.

Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study.

Jakubowski DB, Cerussi AE, Bevilacqua F, Shah N, Hsiang D, Butler J, Tromberg BJ.

J Biomed Opt. 2004 Jan-Feb;9(1):230-8.

PMID:
14715078
11.

Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.

Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW.

Breast Cancer Res Treat. 2005 May;91(1):1-10.

PMID:
15868426
12.

Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer?

Pakalniskis MG, Wells WA, Schwab MC, Froehlich HM, Jiang S, Li Z, Tosteson TD, Poplack SP, Kaufman PA, Pogue BW, Paulsen KD.

Radiology. 2011 May;259(2):365-74. doi: 10.1148/radiol.11100699. Epub 2011 Mar 15.

13.

Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy.

Martincich L, Montemurro F, Cirillo S, Marra V, De Rosa G, Ponzone R, Aglietta M, Regge D.

Radiol Med. 2003 Jul-Aug;106(1-2):51-8. English, Italian.

PMID:
12951551
14.

Vascularity change and tumor response to neoadjuvant chemotherapy for advanced breast cancer.

Kuo WH, Chen CN, Hsieh FJ, Shyu MK, Chang LY, Lee PH, Liu LY, Cheng CH, Wang J, Chang KJ.

Ultrasound Med Biol. 2008 Jun;34(6):857-66. doi: 10.1016/j.ultrasmedbio.2007.11.011. Epub 2008 Mar 28.

PMID:
18374468
15.
16.

Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.

Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, Barbieri MR, Romero Acuña LA, Romero Acuña JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT, Leone BA.

Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31.

PMID:
9554929
17.

Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.

Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, Feig BW, McNeese MD, Hortobagyi GN, Singletary SE.

Cancer J Sci Am. 1998 Jul-Aug;4(4):230-6.

PMID:
9689981
18.

Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.

Sarid D, Ron IG, Sperber F, Stadler Y, Kahan P, Kovner F, Ben-Yosef R, Marmor S, Grinberg Y, Maimon N, Weinstein J, Yaal-Hahoshen N.

Clin Drug Investig. 2006;26(12):691-701.

PMID:
17274676
19.

Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA.

J Clin Oncol. 2008 Sep 20;26(27):4449-57. doi: 10.1200/JCO.2007.15.4385. Epub 2008 Jul 14.

20.

MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.

Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N.

Ann Surg Oncol. 2001 Jul;8(6):549-59.

PMID:
11456056
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk